ClinicalTrials.gg
RecruitingNCT07148791BC19IGG4Updated Sep 3, 2025

Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease

A Phase 2 interventional study of Anti-BCMA-CD19 CAR-T cells in IgG4 Related Disease and B-cell Mediated Autoimmune Disorders, sponsored by Chinese PLA General Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-09-03.

Sponsored by Chinese PLA General Hospital · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Immunoglobulin G4-Related Disease with a site in China — 24 open to participants now, 28 under way, 5 of them phase 3. Immunoglobulin G4-Related Disease · China.

Planned enrollment
36th of 37
9 · median 58
Started
2025
with 7 others
Phase 2
5 of 41
4 open now
Primary completion
2027-09
later than 14 of 27 live
Registered
31st of 41
by date
Lead sponsor
3 of 41
Chinese PLA General Hospital

Among the 41 studies in Immunoglobulin G4-Related Disease with a site in China, this one is the 36th largest by planned enrollment of the 37 interventional ones that give a count, is one of 8 that started in 2025, is one of 5 in phase 2, reaches primary completion later than 14 of the 27 other live ones, and was the 31st registered.

Immunoglobulin G4-Related Disease

72 studies on the registry are indexed under Immunoglobulin G4-Related Disease; 40 are open to participants now.

Browse Immunoglobulin G4-Related Disease studies →

Open to participants now

24 of the 41 studies in Immunoglobulin G4-Related Disease with a site in China are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 27 Immunoglobulin G4-Related Disease studies recruiting now, 11 (41%) set no upper age limit and 13 (48%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Immunoglobulin G4-Related Disease with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to test the safety and potential benefit of a new immune cell therapy called anti-BCMA-CD19 CAR-T cells in adults (18-75 years) with IgG4-related disease (IgG4-RD) that has come back or not improved after standard treatments such as glucocorticoids or rituximab.

The main questions this study aims to answer are:

  • What medical problems (side effects) occur after receiving anti-BCMA-CD19 CAR-T cell therapy?
  • Does anti-BCMA-CD19 CAR-T cell therapy improve IgG4-RD disease activity scores at 12 weeks and 26 weeks?

Participants will:

  • Have their own blood immune cells collected by a procedure called leukapheresis
  • Receive short-term chemotherapy to prepare the immune system
  • Receive one intravenous infusion of anti-BCMA-CD19 CAR-T cells
  • Return for regular clinic visits over 26 weeks for safety checks, blood tests, and imaging
  • May be followed for up to one year in total
Read the detailed description

This is a Phase 2, open-label, single-arm exploratory clinical trial using a 3+3 dose-escalation design to assess the safety, feasibility, and preliminary efficacy of autologous anti-BCMA-CD19 chimeric antigen receptor T (CAR-T) cell therapy in patients with relapsed or refractory IgG4-related disease (IgG4-RD).

Background IgG4-RD is a chronic, immune-mediated fibroinflammatory disorder that can involve multiple organs, including the pancreas, bile ducts, salivary glands, kidneys, lungs, and retroperitoneum. Although standard treatments such as glucocorticoids and anti-CD20 monoclonal antibodies (e.g., rituximab) are effective for most patients, some develop treatment resistance, frequent relapses, or contraindications to conventional immunosuppressive agents. This creates an unmet clinical need for novel therapeutic strategies.

Recent translational studies show that IgG4-RD lesions often contain abundant CD19+ B cells, plasmablasts, and long-lived plasma cells expressing B-cell maturation antigen (BCMA), many of which may be resistant to conventional B-cell depletion. Dual-target CAR-T cells directed against both CD19 and BCMA may achieve more complete depletion of pathogenic B-lineage cells and offer a promising treatment for refractory IgG4-RD.

Methods Eligible participants will undergo leukapheresis for autologous peripheral blood mononuclear cell (PBMC) collection. Cells will be transduced ex vivo with a lentiviral vector encoding a CAR construct targeting CD19 and BCMA, then expanded and prepared for infusion. Lymphodepletion chemotherapy with cyclophosphamide (250 mg/m\^2/day, IV) and fludarabine (30 mg/m\^2/day, IV) will be given on Days -5 to -3. The doses of fludarabine and cyclophosphamide may be adjusted based on the patient's condition.

CAR-T cells will be infused on Day 0 at one of three sequential dose levels (1×10\^6, 2×10\^6, or 3×10\^6 CAR+ T cells/kg, ±20%). Participants will be followed regularly for safety (adverse events [AEs], serious adverse events [SAEs], cytokine release syndrome [CRS], immune effector cell-associated neurotoxicity syndrome [ICANS]), pharmacokinetics (CAR-T cell expansion and persistence), and immunologic responses.

Endpoints The primary endpoints are safety (incidence of dose-limiting toxicities [DLTs] within 28 days post-infusion) and efficacy (change in IgG4-RD Responder Index [RI] at Week 12 and Week 26). Secondary endpoints include changes in target lesion size, serum IgG4, IgE, and eosinophil counts, as well as histopathologic changes in affected tissue.

Exploratory Analyses Exploratory studies will assess immune cell profiles in blood, bone marrow, and tissue biopsies using flow cytometry, multiplex cytokine assays, and spatial or single-cell transcriptomic techniques.

03

Conditions studied

  • IgG4 Related Disease
  • B-cell Mediated Autoimmune Disorders

Keywords

  • IgG4 related disease
  • CAR-T therapy
  • BCMA/CD19 CAR-T
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To participate, subjects must meet all of the following criteria:

  1. Aged 18 to 75 years, inclusive, regardless of sex.
  2. Meet the 2019 ACR/EULAR classification criteria for IgG4-related disease.
  3. Involvement of two or more important systems/sites (including but not limited to the pancreas, bile ducts, kidneys and dura mater).
  4. IgG4-RD: The disease either remains active after 3 months of and/or rituximab therapy or relapses within 6 months post-treatment.
  5. Important organ function meeting the following conditions:

    • Bone marrow: (i) ≥1×10\^9/L (excluding disease-related neutropenia); (ii) ≥60 g/L.
    • Hepatic function: ≤3× (elevation caused by disease may be excluded); AST≤3×ULN (elevation caused by disease may be excluded); ≤1.5×ULN (elevation caused by disease may be excluded).
    • Renal function: (Cockcroft-Gault formula) ≥30 ml/min (excluding acute decline due to disease).
    • Coagulation: (INR) ≤ 1.5×ULN, prothrombin time (PT) ≤ 1.5×ULN
    • Cardiac function: stable hemodynamics.
  6. Women of and male subjects with partners of childbearing potential must use medically accepted or abstain during study treatment and for at least 12 months after the end of treatment. Women of childbearing potential must have a negative serum HCG test within 7 days before enrollment and must not be breastfeeding.
  7. Voluntary participation in this clinical study with signed and willingness to comply with study procedures and follow-up.
  8. Patent superficial peripheral veins adequate for intravenous infusion.

Exclusion criteria

Exclusion Criteria:

Subjects will be excluded if any of the following criteria are met:

  1. History of severe drug allergy or allergic constitution.
  2. Current or suspected uncontrollable or treatment-requiring fungal, bacterial, viral or other infections.
  3. Central nervous system disease (excluding disease-related epilepsy, psychosis, organic brain syndrome, cerebrovascular accident, encephalitis or central nervous system vasculitis).
  4. Cardiac insufficiency that precludes participation.
  5. Congenital immunoglobulin deficiency.
  6. Congenital malformation or nutritional disorder causing severe organ impairment.
  7. History of within the past five years.
  8. End-stage renal failure.
  9. Positive surface antigen and hepatitis B core antibody with HBV-DNA titers above the assay limit of detection; positive antibody with HCV-RNA positivity; positive antibody; positive syphilis serology.
  10. Psychiatric disorders or severe cognitive impairment.
  11. Participation in other clinical trials within three months before enrollment.
  12. Receipt of any drug within 12 weeks before screening or within five half-lives of the agent (whichever is longer).
  13. Pregnant or intending to become pregnant.
  14. Any other reason deemed by the investigator to preclude enrollment.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (estimated)

Study arms

  • Experimental
    Anti-BCMA-CD19 CAR-T cells

    Participants will undergo leukapheresis for autologous T-cell collection, followed by ex vivo transduction with a lentiviral vector encoding a dual-target CAR against BCMA and CD19. After lymphodepletion chemotherapy with fludarabine (30 mg/m²/day) and cyclophosphamide (250 mg/m²/day) for 3 consecutive days, participants will receive a single intravenous infusion of the manufactured CAR-T cells at the assigned dose level. Post-infusion, participants will be monitored for safety, tolerability, and preliminary efficacy through Week 52.

    Biological: Anti-BCMA-CD19 CAR-T cells

Interventions

  • BiologicalAnti-BCMA-CD19 CAR-T cells

    Anti-BCMA-CD19 CAR-T cell injection is an autologous, dual-target chimeric antigen receptor T-cell therapy designed to target CD19 and BCMA antigens. Peripheral blood mononuclear cells (PBMCs) are collected from each participant and modified ex vivo using lentiviral transduction to express the CAR construct. Lymphodepletion with cyclophosphamide (250 mg/m\^2/day, IV) and fludarabine (30 mg/m\^2/day, IV) is administered for 3 days (Day -5 to Day -3). The doses of fludarabine and cyclophosphamide may be adjusted based on the patient's clinical condition. CAR-T cells are infused intravenously on Day 0 at one of three dose levels (1x10\^6, 2x10\^6, or 3x10\^6 CAR+ T cells/kg, ±20%). This product is being investigated in patients with relapsed or refractory IgG4-related disease (IgG4-RD) to assess safety and preliminary efficacy.

    Also known as: BC19, CD19/BCMA dual-target CAR-T cell therapy

06

What researchers measure

Primary outcomes

  1. Safety - Incidence of Dose-Limiting Toxicity (DLT) and Adverse Events Related to CAR-T Cells

    Any grade ≥3 toxicity related to CAR-T cells within 28 days post-infusion is considered a DLT, except: * Grade 3 CRS resolving to ≤ grade 2 within 3 days; * Grade 3/4 TLS \<7 days; * Hematologic: grade 3 neutropenia/anemia/thrombocytopenia at any time or grade 4 \<14 days (\<21 days for thrombocytopenia); other cytopenias excluded; * Non-hematologic: fever (incl. febrile neutropenia), grade 3 diarrhea \<7 days, grade 3 nausea/vomiting \<7 days, grade 3 fatigue \<7 days; * Grade 3/4 elevations in liver enzymes, bilirubin, creatinine, or BUN \<7 days; * Asymptomatic lipase elevation without pancreatitis; * Asymptomatic grade 3 non-hematologic lab abnormality reversible \<7 days (to baseline or ≤ grade 2). Safety monitoring includes AEs, SAEs, AESIs, CRS, and ICANS, with grading and frequency recorded.

    Time frame: Baseline to Week 26

  2. Efficacy - Changes in IgG4-RD RI

    IgG4-RD Responder Index is a validated score used to assess disease activity

    Time frame: Baseline, Week 12 and Week 26

Secondary outcomes

  1. PK: Cmax of CAR-T Cells

    Peak CAR transgene copies in peripheral blood

    Time frame: Baseline to Week 26

  2. PK: Tmax of CAR-T Cells

    Time to peak CAR transgene level

    Time frame: Baseline to Week 26

  3. PK: AUC0-28d of CAR-T Cells

    Area under the curve of CAR transgene copies over 28 days

    Time frame: Baseline, Week 4

  4. PK: AUC0-90d of CAR-T Cells

    Area under the curve of CAR transgene copies over 90 days

    Time frame: Baseline, W12

  5. PK: Persistence (Tlast) of CAR-T Cells

    Last measurable CAR transgene level

    Time frame: Baseline to Week 26

  6. PD: CD19+ B-cell Count

    Flow cytometric quantification of circulating CD19⁺ B cells

    Time frame: Baseline to Week 26

  7. PD: CAR-T Gene Expression

    Changes in CAR-T cell-associated gene expression

    Time frame: Baseline to Week 26

  8. Lesion Size on Imaging

    Radiographic measurement of involved lesion(s)

    Time frame: Baseline, Week 12 and Week 26

  9. Serum IgG4

    Serum IgG4 concentration (mg/dL)

    Time frame: Baseline, Week 12 and Week 26

  10. Serum IgE

    Serum IgE concentration (IU/mL)

    Time frame: Baseline, Week 12 and Week 26

  11. Total IgG

    Total IgG concentration (mg/dL)

    Time frame: Baseline, Week 12 and Week 26

  12. Absolute Eosinophil Count

    Eosinophil count in peripheral blood (cells/µL)

    Time frame: Baseline, Week 12 and Week 26

  13. Histopathology of Lesion

    Semi-quantitative scoring of inflammation, fibrosis, and IgG4⁺ plasma cell infiltration

    Time frame: Baseline, Week 26 or time of B-cell recovery

Other outcomes

  1. Peripheral Blood Immune Cell Subsets

    Quantification and phenotyping of T, B, NK, monocyte/macrophage subsets

    Time frame: Baseline and Week 26

  2. B-cell Subpopulations in Lesion Tissue

    Flow cytometry and histology of tissue-derived B cells

    Time frame: Baseline and Week 26

  3. Plasma Cytokine and Chemokine Levels

    Multiplex assays of plasma cytokines and chemokines

    Time frame: Baseline and Week 26

  4. Immune Cell Functional Status

    Proliferation, activation, and exhaustion marker expression (MFI)

    Time frame: Baseline and Week 26

07

Study locations

1 of 1 sites recruiting
  • Department of Rheumatology and Immunology, the First Medical Center, Chinese PLA General Hospital
    Beijing, Beijing Municipality 100853, China
    Recruiting
    • YUFEI GUO, M.M. · Contactdt_guoyf0412@outlook.com · +86 010-55499314
    • JIAN ZHU, M.D./Ph.D. · Principal investigator
    • YIWEN WANG, M.D. · Sub investigator
08

References and documents

Publications

  • Sun Y, Huang S, Zhang B, Peng Y, Lu H, Jia Y, Sun R, Zhang F, Zhou J, Peng L, Li M, Zhang W, Fei Y. Efficacy and safety of anti-CD19 CAR-T in a mouse model of IgG4-related disease. Int Immunopharmacol. 2025 Jan 3;145:113779. doi: 10.1016/j.intimp.2024.113779. Epub 2024 Dec 12. PubMed 39672025 ↗
  • Zhang Y, Liu D, Zhang Z, Huang X, Cao J, Wang G, Du X, Wang Z, Yang M, Luo T, Liu S, Zhang W, Sheng Y, Li H, Zhang W, Chen H, Zhang S, Wang X, Meng W, Zong S, Shi M, Zheng J, Cui G. Bispecific BCMA/CD19 targeted CAR-T cell therapy forces sustained disappearance of symptoms and anti-acetylcholine receptor antibodies in refractory myasthenia gravis: a case report. J Neurol. 2024 Jul;271(7):4655-4659. doi: 10.1007/s00415-024-12367-4. Epub 2024 Apr 11. No abstract available. PubMed 38602546 ↗
  • Shi M, Wang J, Huang H, Liu D, Cheng H, Wang X, Chen W, Yan Z, Sang W, Qi K, Li D, Zhu F, Li Z, Qiao J, Wu Q, Zeng L, Fei X, Gu W, Miao Y, Xu K, Zheng J, Cao J. Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial. Nat Commun. 2024 Apr 20;15(1):3371. doi: 10.1038/s41467-024-47801-8. PubMed 38643278 ↗
  • Wang Y, Cao J, Gu W, Shi M, Lan J, Yan Z, Jin L, Xia J, Ma S, Liu Y, Li H, Pan B, Chen W, Fei X, Wang C, Xie X, Yu L, Wang G, Li H, Jing G, Cheng H, Zhu F, Sun H, Sang W, Li D, Li Z, Zheng J, Xu K. Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma. J Clin Oncol. 2022 Jul 10;40(20):2246-2256. doi: 10.1200/JCO.21.01676. Epub 2022 Mar 25. PubMed 35333600 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Access to the data underlying this study can be obtained from the corresponding author upon reasonable request and subject to any required ethical approvals.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2025; primary completion for Sep 2027, 23 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2025
First posted
Aug 29, 2025
StartEst.
Sep 5, 2025
Primary completionEst.
Sep 1, 2027
CompletionEst.
Dec 31, 2029
Last update
Sep 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07148791
Collaborators
Xuzhou Medical University
Responsible party
Jian Zhu (Chief Physician and Professor, Department of Rheumatology and Immunology, First Medical Center, Chinese PLA General Hospital, Chinese PLA General Hospital) — Principal investigator
First posted
Aug 29, 2025
Start date
Sep 5, 2025 (estimated)
Primary completion
Sep 1, 2027 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Sep 3, 2025

Study contacts

YIWEN WANG, M.D.
Contact
yiwenvera@163.com
+86 010-55499314
YUFEI GUO, M.M.
Contact
dt_guoyf0412@outlook.com
+86 010-55499314
JIAN ZHU, M.D./Ph.D.
principal investigator · Department of Rheumatology and Immunology, the First Medical Center, Chinese PLA General Hospital, Beijing

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion